Open AccessComparing effectiveness of various decongestants in the treatment of acute infectious rhinitis
Author(s) -
M.R. Bogomilsky,
Е Ю Радциг,
Н. Д. Пивнева,
O. Kesya
Publication year - 2022
Publication title -
rossijskij vestnik perinatologii i pediatrii
Language(s) - English
Resource type - Journals
eISSN - 2500-2228
pISSN - 1027-4065
DOI - 10.21508/1027-4065-2021-66-6-129-133
Subject(s) - medicine , nasal administration , randomized controlled trial , inclusion and exclusion criteria , clinical trial , prospective cohort study , anesthesia , surgery , pharmacology , alternative medicine , pathology
Rhinitis is characterized by nonspecific symptoms, but they reduce the quality of life as much as possible. Within the framework of this work, the clinical efficacy of drugs based on tuaminoheptane and xylometazoline was evaluated. To achieve this goal, the authors initiated a prospective single-center non-randomized comparative pilot study, the task of which was to compare the effectiveness of intranasal drugs containing tuaminoheptane sulfate and acetylcysteine (Rinofluimucil) and xylometazoline + seawater in pediatric patients with acute uncomplicated rhinitis. Characteristics of children and research methods. The study included patients who met the inclusion / exclusion criteria, they were divided into 2 groups after a standard ENT examination (patients of Group 1 were prescribed with tuaminoheptane sulfate and acetylcysteine (Rinofluimucil), patients of Group 2 were prescribed with a combination of xylometazoline and sea water. The study included 61 patients (32 boys and 19 girls aged 4 to 16 years): 30 patients in Group 1 (tuaminoheptane sulfate and acetylcysteine, Rinofluimucil) and 31 patients in Group 2 (xylometazoline + sea water); comparable by sex and age. Results. Comparison of the patients’ condition at the beginning and at the end of the treatment course demonstrated that both drugs had a therapeutic effect: for each of the assessed indicators in both study groups, there was a pronounced positive trend (statistically significant for all studied symptoms, p <0.01). None of the observed patients during treatment demonstrated unwanted side effects and complications in the middle ear. Conclusion. Intranasal use of a combination of tuaminoheptane sulfate and acylcysteine (Rinofluimucil) has shown efficacy comparable to that of an intranasal spray containing xylometazoline in the treatment of acute uncomplicated rhinitis in children. The advantage of a drug based on tuaminoheptane is the expected gentle effect on the mucous membrane of the nasal cavity and the additional therapeutic effect of the original acetylcysteine, which is characteristic of Rinofluimucil.